ARGX

argenx SE

385.38 USD
-8.11 (-2.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

argenx SE stock is down -4.46% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 67% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 16:14 17 May, 2024 450.00 CALL 21 66
22 Feb 17:41 17 Jan, 2025 500.00 CALL 150 0
26 Feb 14:32 15 Mar, 2024 430.00 CALL 25 129
26 Feb 14:46 15 Mar, 2024 410.00 CALL 30 130
26 Feb 15:03 21 Jun, 2024 430.00 CALL 30 111
26 Feb 15:16 21 Jun, 2024 430.00 CALL 30 111
28 Feb 15:20 17 May, 2024 440.00 CALL 20 15
29 Feb 14:54 17 May, 2024 370.00 CALL 12 12
01 Mar 14:32 21 Jun, 2024 350.00 PUT 30 37
01 Mar 14:57 21 Jun, 2024 330.00 PUT 25 122

About argenx SE

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.

  • ScotiaBank
    Fri Mar 1, 12:10
    hold
    confirm
  • JP Morgan
    Fri Mar 1, 11:32
    buy
    confirm
  • Baird
    Fri Mar 1, 07:45
    buy
    confirm
  • HC Wainwright & Co.
    Fri Mar 1, 07:03
    buy
    confirm
  • Wells Fargo
    Tue Feb 20, 11:41
    buy
    confirm
  • Wolfe Research
    Thu Feb 15, 06:24
    hold
    initial